β ₂-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids

Keyphrases

• RGS2 100%
• Adrenoceptor Agonist 100%
• Genomic Mechanisms 100%
• Bronchoprotection 100%
• Spasmogens 50%
• Intracellular Calcium 33%
• Inhaled Corticosteroids 33%
• Bronchoconstriction 33%
• Gene Expression 16%
• Monotherapy 16%
• Asthma 16%
• Clinical Efficacy 16%
• Corticosteroids 16%
• Chronic Obstructive Pulmonary Disease 16%
• Moderate to Severe 16%
• Gene-deficient Mice 16%
• Histamine 16%
• Calcium Flux 16%
• Combination Therapy 16%
• GTPase-activating Protein 16%
• Leukotriene B4 (LTB4) 16%
• Severe Disease 16%
• Human Aortic Smooth muscle Cells (HASMCs) 16%
• Methacholine 16%
• Protein-coupled Receptor 16%
• Human Airway Smooth muscle 16%
• Disease Activation 16%
• Rational Explanation 16%
• Obstructive Airway Disease 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Glucocorticoid 100%
• Adrenergic Receptor Stimulating Agent 100%
• RGS2 Protein 100%
• Spasmogen 60%
• Bronchoconstriction 40%
• Histamine 20%
• Receptor 20%
• Monotherapy 20%
• Disease 20%
• Combination Therapy 20%
• Asthma 20%
• Chronic Obstructive Lung Disease 20%
• Guanosine Triphosphatase Activating Protein 20%
• Methacholine 20%
• Obstructive Airway Disease 20%